

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
07 October 2021 (07.10.2021)



(10) International Publication Number  
**WO 2021/202604 A1**

- (51) International Patent Classification:  
C12N 7/00 (2006.01) C12N 15/86 (2006.01)
- (21) International Application Number:  
PCT/US2021/024993
- (22) International Filing Date:  
30 March 2021 (30.03.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
63/003,168 31 March 2020 (31.03.2020) US  
63/154,341 26 February 2021 (26.02.2021) US
- (71) Applicants: **SANA BIOTECHNOLOGY, INC.** [US/US];  
188 East Blaine Street, Suite 400, Seattle, Wash-  
ington 98102 (US). **FLAGSHIP PIONEERING INNO-  
VATIONS V, INC.** [US/US]; 55 Cambridge Parkway, 8th  
Floor, Cambridge, Massachusetts 02142 (US).
- (72) Inventors: **TRUDEAU, Kyle Marvin**; 188 East Blaine  
Street, Suite 400, Seattle, Washington 98102 (US). **BAN-  
DORO, Christopher**; 188 East Blaine Street, Suite 400,  
Seattle, Washington 98102 (US). **MACKENZIE, Lauren  
Pepper**; 188 East Blaine Street, Suite 400, Seattle, Wash-  
ington 98102 (US). **SHAH, Jagesh Vijaykumar**; 188 East  
Blaine Street, Suite 400, Seattle, Washington 98102 (US).  
**VON MALTZAHN, Geoffrey A.**; 55 Cambridge Park-  
way, 8th Floor, Cambridge, Massachusetts 02142 (US).

**RUBENS, Jacob Rosenblum**; 55 Cambridge Parkway,  
8th Floor, Cambridge, Massachusetts 02142 (US). **MEE,  
Michael Travis**; 55 Cambridge Parkway, 8th Floor, Cam-  
bridge, Massachusetts 02142 (US).


(74) Agent: **ESCAJADILLO, Tamara et al.**; Morrison & For-  
ster LLP, 12531 High Bluff Drive, Suite 100, San Diego,  
California 92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF

FIG 4A



(57) Abstract: Provided herein are lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain. Also provided herein are targeted envelope proteins containing a G protein fused or linked to a binding domain, such as a sdAb variable domain, and polynucleotides encoding such proteins. Also provided are producer cells and compositions containing such targeted lipid particles and methods of making and using the targeted lipid particles.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*